1	Proteome	_	NN	_	_	2	NMOD	_	_
2	analysis	_	NN	_	_	6	VMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	NIH3T3	_	NN	_	_	5	NMOD	_	_
5	cells	_	NNS	_	_	3	PMOD	_	_
6	transformed	_	VBN	_	_	0	ROOT	_	_
7	by	_	IN	_	_	6	VMOD	_	_
8	activated	_	VBN	_	_	9	NMOD	_	_
9	Galpha12	_	NN	_	_	7	PMOD	_	_
10	:	_	:	_	_	6	P	_	_
11	regulation	_	NN	_	_	6	VMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	leukemia-associated	_	JJ	_	_	15	NMOD	_	_
14	protein	_	NN	_	_	15	NMOD	_	_
15	SET	_	NN	_	_	12	PMOD	_	_
16	.	_	.	_	_	6	P	_	_
		
1	Galpha(12)	_	RB	_	_	13	VMOD	_	_
2	,	_	,	_	_	13	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	alpha-subunit	_	NN	_	_	13	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	8	NMOD	_	_
7	G12	_	NN	_	_	8	NMOD	_	_
8	family	_	NN	_	_	5	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	heterotrimeric	_	JJ	_	_	12	NMOD	_	_
11	G	_	NN	_	_	12	NMOD	_	_
12	proteins	_	NNS	_	_	9	PMOD	_	_
13	is	_	VBZ	_	_	0	ROOT	_	_
14	involved	_	VBN	_	_	13	VC	_	_
15	in	_	IN	_	_	14	VMOD	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	regulation	_	NN	_	_	15	PMOD	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	cell	_	NN	_	_	20	NMOD	_	_
20	proliferation	_	NN	_	_	18	PMOD	_	_
21	and	_	CC	_	_	20	COORD	_	_
22	neoplastic	_	JJ	_	_	23	NMOD	_	_
23	transformation	_	NN	_	_	21	CONJ	_	_
24	.	_	.	_	_	13	P	_	_
		
1	GTPase-deficient	_	JJ	_	_	5	NMOD	_	_
2	,	_	,	_	_	5	P	_	_
3	constitutively	_	RB	_	_	4	AMOD	_	_
4	activated	_	VBN	_	_	5	NMOD	_	_
5	mutant	_	NN	_	_	13	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Galpha(12)	_	NN	_	_	6	PMOD	_	_
8	(	_	(	_	_	9	P	_	_
9	Galpha(12)Q229L	_	NN	_	_	5	PRN	_	_
10	or	_	CC	_	_	9	COORD	_	_
11	Galpha(12)QL	_	NN	_	_	10	CONJ	_	_
12	)	_	)	_	_	9	P	_	_
13	has	_	VBZ	_	_	0	ROOT	_	_
14	been	_	VBN	_	_	13	VC	_	_
15	previously	_	RB	_	_	14	VMOD	_	_
16	shown	_	VBN	_	_	14	VC	_	_
17	to	_	TO	_	_	16	VMOD	_	_
18	induce	_	VB	_	_	17	IM	_	_
19	oncogenic	_	JJ	_	_	20	NMOD	_	_
20	transformation	_	NN	_	_	18	VMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	NIH3T3	_	NN	_	_	23	NMOD	_	_
23	cells	_	NNS	_	_	21	PMOD	_	_
24	promoting	_	VBG	_	_	20	NMOD	_	_
25	serum-	_	NN	_	_	24	PMOD	_	_
26	and	_	CC	_	_	25	COORD	_	_
27	anchorage-independent	_	JJ	_	_	28	NMOD	_	_
28	growth	_	NN	_	_	26	CONJ	_	_
29	.	_	.	_	_	13	P	_	_
		
1	Reduced	_	VBN	_	_	7	NMOD	_	_
2	growth-factor	_	NN	_	_	7	NMOD	_	_
3	dependent	_	JJ	_	_	2	AMOD	_	_
4	,	_	,	_	_	2	P	_	_
5	autonomous	_	JJ	_	_	2	COORD	_	_
6	cell	_	NN	_	_	7	NMOD	_	_
7	growth	_	NN	_	_	8	VMOD	_	_
8	forms	_	VBZ	_	_	0	ROOT	_	_
9	a	_	DT	_	_	12	NMOD	_	_
10	critical	_	JJ	_	_	12	NMOD	_	_
11	defining	_	VBG	_	_	12	NMOD	_	_
12	point	_	NN	_	_	8	VMOD	_	_
13	at	_	IN	_	_	18	VMOD	_	_
14	which	_	WDT	_	_	13	PMOD	_	_
15	a	_	DT	_	_	17	NMOD	_	_
16	normal	_	JJ	_	_	17	NMOD	_	_
17	cell	_	NN	_	_	18	VMOD	_	_
18	turns	_	NNS	_	_	12	NMOD	_	_
19	into	_	IN	_	_	18	VMOD	_	_
20	an	_	DT	_	_	22	NMOD	_	_
21	oncogenic	_	JJ	_	_	22	NMOD	_	_
22	one	_	NN	_	_	19	PMOD	_	_
23	.	_	.	_	_	8	P	_	_
		
1	To	_	TO	_	_	17	VMOD	_	_
2	identify	_	VB	_	_	1	IM	_	_
3	the	_	DT	_	_	5	NMOD	_	_
4	underlying	_	VBG	_	_	5	NMOD	_	_
5	mechanism	_	NN	_	_	2	VMOD	_	_
6	involved	_	VBN	_	_	5	APPO	_	_
7	in	_	IN	_	_	6	VMOD	_	_
8	such	_	JJ	_	_	11	NMOD	_	_
9	growth-factor/serum	_	JJ	_	_	11	NMOD	_	_
10	independent	_	JJ	_	_	11	NMOD	_	_
11	growth	_	NN	_	_	7	PMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	Galpha(12)QL-transformed	_	JJ	_	_	14	NMOD	_	_
14	NIH3T3	_	NN	_	_	12	PMOD	_	_
15	,	_	,	_	_	17	P	_	_
16	we	_	PRP	_	_	17	VMOD	_	_
17	carried	_	VBD	_	_	0	ROOT	_	_
18	out	_	RP	_	_	17	PRT	_	_
19	a	_	DT	_	_	23	NMOD	_	_
20	two-dimensional	_	JJ	_	_	23	NMOD	_	_
21	differential	_	JJ	_	_	23	NMOD	_	_
22	proteome	_	NN	_	_	23	NMOD	_	_
23	analysis	_	NN	_	_	17	VMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	Galpha(12)QL-transformed	_	JJ	_	_	27	NMOD	_	_
26	NIH3T3	_	NN	_	_	27	NMOD	_	_
27	cells	_	NNS	_	_	24	PMOD	_	_
28	and	_	CC	_	_	27	COORD	_	_
29	cells	_	NNS	_	_	28	CONJ	_	_
30	expressing	_	VBG	_	_	29	APPO	_	_
31	vector	_	NN	_	_	32	NMOD	_	_
32	control	_	NN	_	_	30	VMOD	_	_
33	.	_	.	_	_	17	P	_	_
		
1	This	_	DT	_	_	2	NMOD	_	_
2	analysis	_	NN	_	_	3	VMOD	_	_
3	revealed	_	VBD	_	_	0	ROOT	_	_
4	a	_	DT	_	_	5	NMOD	_	_
5	total	_	NN	_	_	3	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	22	_	CD	_	_	8	NMOD	_	_
8	protein-spots	_	NNS	_	_	6	PMOD	_	_
9	whose	_	WP$	_	_	10	NMOD	_	_
10	expression	_	NN	_	_	11	VMOD	_	_
11	was	_	VBD	_	_	8	NMOD	_	_
12	altered	_	VBN	_	_	11	VC	_	_
13	by	_	IN	_	_	12	VMOD	_	_
14	more	_	JJR	_	_	13	PMOD	_	_
15	than	_	IN	_	_	14	NMOD	_	_
16	3-folds	_	NNS	_	_	15	PMOD	_	_
17	.	_	.	_	_	3	P	_	_
		
1	Two	_	CD	_	_	5	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	these	_	DT	_	_	4	NMOD	_	_
4	spots	_	NNS	_	_	2	PMOD	_	_
5	were	_	VBD	_	_	0	ROOT	_	_
6	identified	_	VBN	_	_	5	VC	_	_
7	by	_	IN	_	_	6	VMOD	_	_
8	MALDI-MS	_	NN	_	_	9	NMOD	_	_
9	analysis	_	NN	_	_	7	PMOD	_	_
10	as	_	IN	_	_	6	VMOD	_	_
11	proliferating	_	JJ	_	_	14	NMOD	_	_
12	cell	_	NN	_	_	14	NMOD	_	_
13	nuclear	_	JJ	_	_	14	NMOD	_	_
14	antigen	_	NN	_	_	10	PMOD	_	_
15	(	_	(	_	_	16	P	_	_
16	PCNA	_	NN	_	_	14	PRN	_	_
17	)	_	)	_	_	16	P	_	_
18	and	_	CC	_	_	14	COORD	_	_
19	myeloid-leukemia-associated	_	JJ	_	_	21	NMOD	_	_
20	SET	_	NN	_	_	21	NMOD	_	_
21	protein	_	NN	_	_	18	CONJ	_	_
22	.	_	.	_	_	5	P	_	_
		
1	The	_	DT	_	_	3	NMOD	_	_
2	increased	_	VBN	_	_	3	NMOD	_	_
3	expressions	_	NNS	_	_	10	VMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	these	_	DT	_	_	6	NMOD	_	_
6	proteins	_	NNS	_	_	4	PMOD	_	_
7	in	_	IN	_	_	3	NMOD	_	_
8	Galpha(12)QL	_	NN	_	_	9	NMOD	_	_
9	cells	_	NNS	_	_	7	PMOD	_	_
10	were	_	VBD	_	_	0	ROOT	_	_
11	validated	_	VBN	_	_	10	VC	_	_
12	by	_	IN	_	_	11	VMOD	_	_
13	immunoblot	_	NN	_	_	14	NMOD	_	_
14	analysis	_	NN	_	_	12	PMOD	_	_
15	.	_	.	_	_	10	P	_	_
		
1	Furthermore	_	RB	_	_	9	VMOD	_	_
2	,	_	,	_	_	9	P	_	_
3	transient	_	JJ	_	_	5	NMOD	_	_
4	transfection	_	NN	_	_	5	NMOD	_	_
5	studies	_	NNS	_	_	9	VMOD	_	_
6	with	_	IN	_	_	5	NMOD	_	_
7	NIH3T3	_	NN	_	_	8	NMOD	_	_
8	cells	_	NNS	_	_	6	PMOD	_	_
9	indicated	_	VBD	_	_	0	ROOT	_	_
10	that	_	IN	_	_	9	VMOD	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	expression	_	NN	_	_	17	VMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	activated	_	VBN	_	_	15	NMOD	_	_
15	Galpha(12)	_	NN	_	_	13	PMOD	_	_
16	readily	_	RB	_	_	17	VMOD	_	_
17	increased	_	VBD	_	_	10	SUB	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	expression	_	NN	_	_	17	VMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	SET	_	NN	_	_	22	NMOD	_	_
22	protein	_	NN	_	_	20	PMOD	_	_
23	by	_	IN	_	_	17	VMOD	_	_
24	24	_	CD	_	_	25	NMOD	_	_
25	h	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	9	P	_	_
		
1	As	_	IN	_	_	19	VMOD	_	_
2	SET	_	NN	_	_	3	VMOD	_	_
3	has	_	VBZ	_	_	1	SUB	_	_
4	been	_	VBN	_	_	3	VC	_	_
5	previously	_	RB	_	_	4	VMOD	_	_
6	reported	_	VBN	_	_	4	VC	_	_
7	to	_	TO	_	_	6	VMOD	_	_
8	be	_	VB	_	_	7	IM	_	_
9	an	_	DT	_	_	10	NMOD	_	_
10	inhibitor	_	NN	_	_	8	VMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	phosphatase	_	NN	_	_	13	NMOD	_	_
13	PP2A	_	NN	_	_	11	PMOD	_	_
14	,	_	,	_	_	19	P	_	_
15	the	_	DT	_	_	18	NMOD	_	_
16	nuclear	_	JJ	_	_	18	NMOD	_	_
17	phosphatase	_	NN	_	_	18	NMOD	_	_
18	activity	_	NN	_	_	19	VMOD	_	_
19	was	_	VBD	_	_	0	ROOT	_	_
20	monitored	_	VBN	_	_	19	VC	_	_
21	in	_	IN	_	_	20	VMOD	_	_
22	cells	_	NNS	_	_	21	PMOD	_	_
23	expressing	_	VBG	_	_	22	APPO	_	_
24	activated	_	JJ	_	_	25	NMOD	_	_
25	Galpha(12)	_	NN	_	_	23	VMOD	_	_
26	.	_	.	_	_	19	P	_	_
		
1	Our	_	PRP$	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	3	VMOD	_	_
3	indicate	_	VBP	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	VMOD	_	_
5	the	_	DT	_	_	8	NMOD	_	_
6	nuclear	_	JJ	_	_	8	NMOD	_	_
7	phosphatase	_	NN	_	_	8	NMOD	_	_
8	activity	_	NN	_	_	9	VMOD	_	_
9	is	_	VBZ	_	_	4	SUB	_	_
10	inhibited	_	VBN	_	_	9	VC	_	_
11	by	_	IN	_	_	10	VMOD	_	_
12	greater	_	JJR	_	_	14	DEP	_	_
13	than	_	IN	_	_	14	DEP	_	_
14	50	_	CD	_	_	15	NMOD	_	_
15	%	_	NN	_	_	11	PMOD	_	_
16	in	_	IN	_	_	15	NMOD	_	_
17	Galpha(12)QL	_	NN	_	_	18	NMOD	_	_
18	cells	_	NNS	_	_	16	PMOD	_	_
19	compared	_	VBN	_	_	10	VMOD	_	_
20	to	_	TO	_	_	19	PMOD	_	_
21	vector	_	NN	_	_	23	NMOD	_	_
22	control	_	NN	_	_	23	NMOD	_	_
23	cells	_	NNS	_	_	20	PMOD	_	_
24	.	_	.	_	_	3	P	_	_
		
1	Thus	_	RB	_	_	11	VMOD	_	_
2	,	_	,	_	_	11	P	_	_
3	our	_	PRP$	_	_	4	NMOD	_	_
4	results	_	NNS	_	_	11	VMOD	_	_
5	from	_	IN	_	_	4	NMOD	_	_
6	differential	_	JJ	_	_	8	NMOD	_	_
7	proteome	_	NN	_	_	8	NMOD	_	_
8	analysis	_	NN	_	_	5	PMOD	_	_
9	presented	_	VBN	_	_	4	APPO	_	_
10	here	_	RB	_	_	9	VMOD	_	_
11	report	_	VBP	_	_	0	ROOT	_	_
12	for	_	IN	_	_	11	VMOD	_	_
13	the	_	DT	_	_	15	NMOD	_	_
14	first	_	JJ	_	_	15	NMOD	_	_
15	time	_	NN	_	_	12	PMOD	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	role	_	NN	_	_	11	VMOD	_	_
18	for	_	IN	_	_	17	NMOD	_	_
19	SET	_	NN	_	_	18	PMOD	_	_
20	in	_	IN	_	_	17	NMOD	_	_
21	Galpha(12)-mediated	_	JJ	_	_	23	NMOD	_	_
22	signaling	_	NN	_	_	23	NMOD	_	_
23	pathways	_	NNS	_	_	20	PMOD	_	_
24	and	_	CC	_	_	17	COORD	_	_
25	a	_	DT	_	_	26	NMOD	_	_
26	role	_	NN	_	_	24	CONJ	_	_
27	for	_	IN	_	_	26	NMOD	_	_
28	Galpha(12)	_	NN	_	_	27	PMOD	_	_
29	in	_	IN	_	_	26	NMOD	_	_
30	the	_	DT	_	_	31	NMOD	_	_
31	regulation	_	NN	_	_	29	PMOD	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	the	_	DT	_	_	36	NMOD	_	_
34	leukemia-associated	_	JJ	_	_	36	NMOD	_	_
35	SET-protein	_	NN	_	_	36	NMOD	_	_
36	expression	_	NN	_	_	32	PMOD	_	_
37	.	_	.	_	_	11	P	_	_
		
